Overview
Status
Active
Registry date
2001-06-27
Share capital
27 130 000,00 PLN
Registered address
Aleje Jerozolimskie 134, 02-305 Warszawa, Poland
Electronic delivery address
AE:PL-67724-36747-WHBVA-19
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 247.10mMedianUSD 816.16kAverageUSD 29.28m
Net profit
This companyUSD 33.38mMedianUSD 8.96kAverageUSD 2.64m
Operating costs
This companyUSD 198.98mMedianUSD 701.47kAverageUSD 19.26m
Assets
This companyUSD 236.96mMedianUSD 800.13kAverageUSD 29.34m
Industry
Bank accounts
Registered as a VAT taxpayer on 2003-11-30. Active
19 1880 0009 0000 0011 0102 5041
32 1880 0009 0000 0011 0102 5001
41 1880 0009 0000 0011 0102 5033
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jul 22, 2026 | Return of additional payments | |
| Feb 28, 2014 | Merger plan | |
| May 6, 2013 | Merger plan |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 12, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $13,949$13,949 | Zarządca Rozliczeń S.A. | |
| Aug 12, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $12,059$12,059 | Zarządca Rozliczeń S.A. |
Tenders
2237 tenders recorded as contractor: 475 national ($20,948,968) and 1762 EU ($4,682,000,410).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Oct 2, 2026 | Dostawa leków do chemioterapii i programów lekowych 2026-2028 | —— | Wojewódzki Szpital Specjalistyczny We Wrocławiu | |
| Oct 2, 2026 | Dostawa leków programowych, onkologicznych, płynów infuzyjnych, erytropoetyny oraz kontrastów | —— | Wojewódzki Szpital Specjalistyczny Nr 4 w Bytomiu | |
| Oct 2, 2026 | Dostawy zestawów do filtracji (tzw. ośmiorniczek) przeznaczonych do otrzymywania ubogoleukocytarnego koncentratu krwinek płytkowych (UKKP). | —— | Regionalne Centrum Krwiodawstwa I Krwiolecznictwa w Gdańsku |
Authorized Representatives
Magdalena Aleksandra Przygodzka — Attorney-in-fact (joint)
Maciej Henryk Chmielowski — Management Board Member
Izabella Grabska — Attorney-in-fact (joint)
Tomasz Michał Halik — Management Board Member
Manner of representation
In the case of a multi-member management board, two members of the management board jointly or one member of the management board jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Fresenius Kabi Ag | 226,080 | $3,053,484.60 | 41.6661% |
Others | 316,520 | $4,274,986.49 | 58.3339% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Maciej Henryk Chmielowski (65) | Członek zarządu spółki dla której podmiotem kontrolującym jest spółka giełdowa z siedzibą w niemczech | |
Tomasz Michał Halik (49) | Członek zarządu spółki dla której podmiotem kontrolującym jest spółka giełdowa z siedzibą w niemczech |
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Dom Medicasp. z o.o. | 270,097.24 USD | 99.99% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | — | glagolica.eu |
Change history
| Date | Event | |
|---|---|---|
| 2018-12-06 | Address change (Al. Aleje Jerozolimskie 134, 02-305, Warszawa → Aleje Jerozolimskie 134, 02-305, Warszawa) | |
| 2015-12-02 | Address change (Hrubieszowska 2, 01-209, Warszawa → Al. Aleje Jerozolimskie 134, 02-305, Warszawa) | |
| 2012-11-27 | Share capital change (14,130,000.00 PLN → 27,130,000.00 PLN) | |
| 2009-09-07 | Share capital change (11,304,000.00 PLN → 14,130,000.00 PLN) | |
| 2005-06-07 | Address change (Aleje Jerozolimskie 146d, 02-305, Warszawa → Hrubieszowska 2, 01-209, Warszawa) |
FAQ
The main business activity of Fresenius Kabi Polska focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on June 27, 2001.
The headquarters is located at: Aleje Jerozolimskie 134, 02-305 Warszawa.
The share capital of the company is PLN 27,130,000 (approx. $7.3 million).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $206,850,915, representing an increase of 12.7% compared to 2023.
Yes, in 2024 the company was profitable, achieving a net profit of $18,227,762, meaning the company increased its profit by 65.5%.
Last updated: 2026-07-15